Trials / Terminated
TerminatedNCT02156674
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naglazyme® | 1 mg per kg of body weight administered once weekly as an intravenous infusion |
Timeline
- Start date
- 2016-01-26
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2014-06-05
- Last updated
- 2020-12-23
- Results posted
- 2020-12-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02156674. Inclusion in this directory is not an endorsement.